The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Reassessment of a proposed molecular classification system for clear cell renal cell cancer (ccRCC): Results from a randomized phase II trial of pazopanib.
Martha P. Mims
No relevant relationships to disclose
Robert C. Gagnon
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Yuan Liu
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Elisabeth I. Heath
No relevant relationships to disclose
Primo Lara
Research Funding - GlaxoSmithKline